FY2025 Earnings Estimate for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings of ($0.89) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Other equities analysts have also recently issued reports about the company. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. Finally, D. Boral Capital reiterated a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Immunic presently has an average rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.20 on Wednesday. The firm has a market cap of $108.09 million, a P/E ratio of -0.98 and a beta of 1.89. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The business’s 50 day simple moving average is $1.07 and its two-hundred day simple moving average is $1.21.

Hedge Funds Weigh In On Immunic

Hedge funds have recently bought and sold shares of the company. State Street Corp raised its holdings in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the last quarter. 683 Capital Management LLC increased its stake in Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after buying an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after buying an additional 22,200 shares during the last quarter. Focus Partners Wealth lifted its position in shares of Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic in the 3rd quarter worth approximately $50,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.